Vir Biotechnology (NYSE:VIR) Now Covered by Barclays

Barclays began coverage on shares of Vir Biotechnology (NYSE:VIR) in a research report issued on Tuesday, The Fly reports. The brokerage set an “overweight” rating and a $25.00 price target on the stock. Barclays‘s price objective would indicate a potential upside of 70.88% from the company’s current price.

A number of other research firms have also recently issued reports on VIR. JPMorgan Chase & Co. assumed coverage on shares of Vir Biotechnology in a research note on Tuesday. They issued an “overweight” rating and a $25.00 target price for the company. Cowen assumed coverage on shares of Vir Biotechnology in a research note on Tuesday. They issued an “outperform” rating for the company.

VIR stock opened at $14.63 on Tuesday. Vir Biotechnology has a 52 week low of $13.39 and a 52 week high of $16.50.

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of Vir Biotechnology stock in a transaction on Wednesday, October 16th. The stock was purchased at an average cost of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of Vir Biotechnology stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.41 per share, with a total value of $14,410,000.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Read More: What is a support level?

The Fly

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.